Immunoscore® is now available in Rectal Cancer for expert clinical centers through an Innovation Access Program Immunoscore® heads up to become the standard precision tool for the “Watch and Wait” strategy in locally...

Positive results on Immunoscore® in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study have been presented at ASCO 2019 HalioDx SAS, an immuno-oncology company pioneering the immunological...

This funding will accelerate the development of Immunoscore® in selected cancers, and support set up of commercial activities in the US This round was led by PSIM fund managed by Bpifrance in the framework of the program ‘Investing...

HalioDx receives CLIA Compliance for its laboratory based in Marseille Immunoscore® Colon, is now available to US patients in selected states with a turnaround time of 10 days Marseille, June 21, 2017 - HalioDx announced today that...

Immunoscore® Colon is the first standardized immune‐based assay for the classification of cancers Immunoscore® has been validated by the Immunoscore® worldwide consortium, led by the SITC (ASCO 2016) Immunoscore® is a...

Presenters: Dr. Bernard Fox, Endowed Chair and Chief, Laboratory of Molecular and Tumor Immunology Providence Cancer Center Dr. Carlo Bifulco, Director of Molecular Pathology and Pathology Informatics Providence Regional...